Developed by researchers in Australia, AOD-9604 was initially investigated as a potential anti-obesity drug due to its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat accumulation)
Human-grade BPC-157 is produced by licensed compounding pharmacies under strict purity, sterility, and potency standards intended for patient use
Peptide-based cancer therapy: opportunity and challenge
These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
Lipids form your cell membranes oxidation here weakens the barrier that keeps harmful substances out and nutrients in
